Gotistobart vs Tremelimumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: CTLA-4 · full Non-Small Cell Lung Cancer pipeline
Gotistobart
Developed by OncoC4, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04140526 (registry estimate)
No aligned efficacy figure on record for this race.
Tremelimumab
Marketed by AstraZeneca and partners
NCT02453282 · Phase 3 · active, not recruiting
The trial was randomized against an active chemotherapy comparator in 1,118 patients, with hard cancer endpoints, but it had no blinding. For tremelimumab, the durvalumab plus tremelimumab comparison with chemotherapy missed both primary endpoints in the PD-L1-high group (overall survival hazard ratio 0.85, p=0.202; progression-free survival hazard ratio 1.05, p=0.705). A well-designed trial with a negative result is graded moderate.
Next expected readout: December 2026 · NCT05000710 (registry estimate)
Reported efficacy
Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).); Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy (Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).): Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) (missed)
Result source: NCT02453282
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Gotistobart | Tremelimumab |
|---|---|---|
| PFS, median | —Trial running · NCT05671510 | 3.9 vs 5.4vs SoC ChemotherapyNCT0245328211 other results
|
| OS, median | —Trial running · NCT05671510 | 11.9 vs 16.3vs DurvalumabNCT024532829 other results
|
| ORR | —Trial running · NCT05671510 | 34.4% vs 35.6%vs DurvalumabNCT024532824 other results
|
| Duration of response, median | —Trial running · NCT05671510 | 7.4 vs 6vs D + SoCNCT031646166 other results
|
PFS, median
- Gotistobart
- —Trial running · NCT05671510
- Tremelimumab
- 3.9 vs 5.4vs SoC ChemotherapyNCT02453282
11 other results
- 3.5 vs 3.5 NCT02352948
- 6.2 vs 5.5 NCT03164616
- 3.9 vs 4.7 NCT02453282
- 2.8 vs 5.5 NCT02453282
- 2.9 vs 2.8 NCT02453282
- 3.5 vs 3.1 NCT02352948
- 2.1 vs 3.1 NCT02352948
- 2 NCT03164772
- 1.8 NCT03164772
- 2 NCT03164772
- 1.8 NCT03164772
OS, median
- Gotistobart
- —Trial running · NCT05671510
- Tremelimumab
- 11.9 vs 16.3vs DurvalumabNCT02453282
9 other results
- 11.5 vs 8.7 NCT02352948
- 14 vs 13.3 NCT03164616
- 11.9 vs 16.3 NCT02453282
- 10.9 vs 12.3 NCT02453282
- 11.2 vs 12.3 NCT02453282
- 11.5 vs 10 NCT02352948
- 6.9 vs 10 NCT02352948
- 23.5 NCT03164772
- 7.5 NCT03164772
ORR
- Gotistobart
- —Trial running · NCT05671510
- Tremelimumab
- 34.4% vs 35.6%vs DurvalumabNCT02453282
4 other results
- 25.3% vs 33.6% NCT02453282
- 24.7% vs 22.2% NCT02453282
- 14.9% vs 6.8% NCT02352948
- 6.7% vs 6.8% NCT02352948
Duration of response, median
- Gotistobart
- —Trial running · NCT05671510
- Tremelimumab
- 7.4 vs 6vs D + SoCNCT03164616
6 other results
- 12.2 vs 10.8 NCT02352948
- 4.7 vs 10.8 NCT02352948
- 9.9 NCT03164772
- 5.8 NCT03164772
- 9.9 NCT03164772
- 5.8 NCT03164772
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Gotistobart: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Gotistobart: 0 of 4 rows · Tremelimumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tremelimumab |
|---|---|
| Dropout rate | 76.3%a NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 5 more resultsn/a: no completion milestone NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 74.1%Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 81.7%Sub-study B: Tremelimumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 78.3%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 91.2%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 5 more results— NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Sub-study B: Tremelimumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 4.3%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 11.8%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 44.2%a NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 5 more results48% NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 37.6%Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 38.3%Sub-study B: Tremelimumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 60.9%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 64.7%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a anaemia 45.5% nausea 41.2% neutropenia 29.7% NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 5 more resultsdecreased appetite 24% fatigue 21.6% nausea 21% NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 diarrhoea 20.8% decreased appetite 19.7% asthenia 17.9% NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 diarrhoea 26.7% pruritus 23.3% decreased appetite 20% NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 decreased appetite 34.8% fatigue 34.8% anaemia 30.4% NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination cough 35.3% fatigue 32.4% nausea 32.4% NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tremelimumab
show 7 more results
show 7 more results
show 5 more results
show 5 more results
show 4 more results
show 4 more results
show 1 more result
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gotistobart's landscape · Tremelimumab's landscape